BriaCell Therapeutics Corp. - *W EXP 02/26/202 (BCTXW)

CUSIP: 10778Y112

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class
Equity / *W EXP 02/26/202
Total 13F shares
877,918
Share change
-332,018
Total reported value
$1,580,000
Price per share
$1.80
Number of holders
10
Value change
-$591,218
Number of buys
4
Number of sells
4

Quarterly Holders Quick Answers

What is CUSIP 10778Y112?
CUSIP 10778Y112 identifies BCTXW - BriaCell Therapeutics Corp. - *W EXP 02/26/202 in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of BriaCell Therapeutics Corp. - *W EXP 02/26/202 (BCTXW) as of Q2 2021

As of 30 Jun 2021, BriaCell Therapeutics Corp. - *W EXP 02/26/202 (BCTXW) was held by 10 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 877,918 shares. The largest 10 holders included ARMISTICE CAPITAL, LLC, Altium Capital Management LP, Murchinson Ltd., Redmond Asset Management, LLC, ZEKE CAPITAL ADVISORS, LLC, Warberg Asset Management LLC, MORGAN STANLEY, Virtu Financial LLC, JANE STREET GROUP, LLC, and Intellectus Partners, LLC. This page lists 10 institutional shareholders reporting positions in this security for the Q2 2021 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.